Table 2.

Summary of recent studies of the use of intravitreal bevacizumab with or without laser therapy for retinopathy of prematurity

Serial #	Author	Year of study	Number of children	Number of eyes	Remarks	Type of therapy
1	António Travassos	2007	3	6	In 24 h, all six injected eyes showed regression of the tunica vasculosa lentis and iris vessel engorgement and disappearance of iris rigidity. In addition, plus disease and retinal proliferation began to regress. None of the eyes required additional treatment.	Laser treatment followed by intravitreal bevacizumab
2	Chung EJ	2007	1	2	Treatment resulted in ROP regression, prompt resolution of plus signs, and neovascular proliferation in both of the two eyes.	Laser treatment followed by intravitreal bevacizumab
3	Mintz Hittner	2008	11	22	Intravitreal injection of bevacizumab was safe and effective in treating stage 3 ROP in zone I and posterior zone II in all 22 eyes.	Intravitreal bevacizumab as monotherapy
4	Shunji Kusaka	2008	14	23	Reduced neovascular activity was seen on fluorescein angiography in 14 eyes. In 3 eyes, tractional retinal detachment progressed after injection.	Laser treatment followed by intravitreal bevacizumab